OSTEOARTHRITIS
Knee OA: MRI assessments reveal early effect of chondroitin sulphate on cartilage loss
Ann Rheum Dis. 2011 Jun;70(6):982-9. doi: 10.1136/ard.2010.140848. Epub 2011 Mar 170 patients with primary knee osteoarthritis were randomized to receive either 800 mg chondroitin sulphate (CS) or a placebo once a day for 6 months to determine the effects of CS on joint cartilage, assessed using magnetic resonance imaging (MRI). Results revealed that 800 mg chondroitin sulphate had an early effect (6 months) on cartilage volume loss and on bone marrow lesions at 12 months. Additionally, patients in the CS group who were taking non-steroidal anti-inflammatory drugs (NSAIDs) had significantly less synovial membrane thickness than patients in the placebo group taking NSAIDs. There were no significant differences in pain, function, stiffness, use of rescue medications or adverse events between the two groups.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
